Journal of Biotechnology & Biomaterials
Open Access

Short Communication

Potential and Challenges for Start-Ups in Japans Biotech Industry

Institute of Liberal Arts and Sciences, Toyohashi University of Technology, Japan

Corresponding Author:

Takao Fujiwara
Institute of Liberal Arts and Sciences, Toyohashi University of Technology
1-1 Hibarigaoka, Tenpaku, Toyohashi, Aichi 441-8580, Japan
Tel: 81-532-44-6946
E-mail: fujiwara@las.tut.ac.jp

Received date: September 22, 2015; Accepted date: October 12, 2015; Published date: October 19, 2015

Citation: Fujiwara T (2015) Potential and Challenges for Start-Ups in Japan’s Biotech Industry. J Biotechnol Biomater 5:204. doi:10.4172/2155-952X.1000204

Copyright: © 2015 Fujiwara T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Although Japan has both a globally rare national M&Ated healthcare program and one of the most extensive life science research capabilities in the world, there is a risk of their divergence due to Japan’s aging citizenry and the domestic pharmaceutical industry. In order to bridge the gap between the research findings and the healthcare welfare with innovative new drugs under a prolonged drug development period and the diminishing grace period before generic drug introduction, we will examine the potential of risk management methods in biotech start-ups from real options, game theory, and start-up ecosystems perspectives. One of the reasons of this article’s focus on the biotech start-ups reflects the trend of the government 2015 policy as ‘Comprehensive reform of social security and tax’ for global drug discovery and start-up founding and the government policy and the economy trend.

Keywords